Seminars in Liver Disease

Papers
(The TQCC of Seminars in Liver Disease is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
70
Mesenchymal Stem Cell Transplantation in Liver Diseases63
59
Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns46
Erratum to: Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics41
Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma35
Beyond Varices: Complications of Cirrhotic Portal Hypertension in Pediatrics32
Influence of Sex in the Development of Liver Diseases29
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?28
Noninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD25
Novel Biomarkers of AKI in Cirrhosis22
Emerging Roles of Spatial Transcriptomics in Liver Research20
Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA19
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD19
Post-Transplant Biliary Strictures: An Updated Review19
Statins in Chronic Liver Disease: Review of the Literature and Future Role19
Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity18
Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?18
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future16
16
Gestational and Developmental Contributors of Pediatric MASLD16
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma15
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol14
Management of Portal vein Thrombosis in Cirrhosis13
Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease13
Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine13
Hepatocellular Carcinoma Chemoprevention with Generic Agents11
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?11
Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype11
Management of Multidrug-Resistant Infections in Cirrhosis11
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis11
Role of Lipogenesis Rewiring in Hepatocellular Carcinoma10
Blinding in Clinical Trials for Chronic Liver Diseases10
Immune Checkpoint Inhibitor-Induced Liver Injury10
Artificial Intelligence in Hepatology: A Narrative Review10
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease10
Environmental Pollutants, Occupational Exposures, and Liver Disease10
10
The Neglected Role of Bile Duct Epithelial Cells in NASH9
Hepatitis Delta Infection: A Clinical Review9
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease8
Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure8
The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors8
Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment8
Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review8
Endoscopic Advances in Hepatology8
Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future8
Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine8
0.03002405166626